Linked Data API

Filter

These are the filters currently being used to limit the search results. Click on the remove filter icon to remove the filter.

date	2017-11-23
answering body	Department of Health
ddp modified	2017-12-01T17:25:05.676Z
min ddp modified	2017-11-30T11:59:01.780Z

Sort by

This list shows the properties that you can sort by. Click on to sort in ascending order and to sort in descending order. The properties that you're currently sorting by are shown at the top of the list. Click on remove this sort to remove a sort and or to reverse the current sort order. Click on the remove all sorting icon to remove all the sorting. Note that sorting can significantly slow down the loading of the page.

View

Choose what information you want to view about each item. There are some pre-defined views, but starred properties are always present no matter what the view. You can star properties by clicking on the icon. The currently starred icons have a icon; clicking on it will unstar the property.

Items per page

Choose how many items to view on each page. The more items you view, the longer the page will take to load.

Show Search Form

Search Results

registered interest

date

exactly:

or between:
and

answering body

answering dept id

answering dept short name

answering dept sort name

hansard heading

house id

legislature


pref label

question text

tabling member printed

uin

answer

is ministerial correction

date of answer

exactly:

or between:
and

answer text

answering member printed

question first answered

answering member


label

tabling member


label

794214

registered interest

date

23/11/2017

answering body

Department of Health

answering dept id

answering dept short name

Health

answering dept sort name

Health

hansard heading

Mefloquine

house id

legislature

25277

pref label	House of Lords

question text

To ask Her Majesty's Government, further to the Written Answer by Earl Howe on 22 November (HL3229), what assessment they have made of the conclusions of the Pharmacovigilance Risk Assessment Committee of the European Medicines Agency in 2014 that: “There is enough evidence … supporting a causal relationship between mefloquine and the occurrence of long lasting and even persistent neuropsychiatric side effects” and a “strong suspicion” that mefloquine can cause “permanent brain damage”.

tabling member printed

The Countess of Mar

uin

HL3532

answer

is ministerial correction

date of answer

05/12/2017

answer text

<p>At its meeting in February 2014, the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency recommended that the product information for mefloquine be amended to state that neuropsychiatric adverse reactions may persist for months, or longer, even after discontinuation of the drug. The PRAC did not recommend that such reactions should be listed as permanent. The United Kingdom product information for mefloquine reflects the final PRAC recommendation.</p><p> </p>

answering member printed

Lord O'Shaughnessy

question first answered

05/12/2017 13:55:03

answering member

4545

label	Biography information for Lord O'Shaughnessy

tabling member

1861

label	Biography information for The Countess of Mar